Oncotelic Therapeutics (OTCQB: OTLC) is strategically positioning itself at the forefront of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle nanomedicine platform, and emerging robotics initiatives, the company is building an integrated technology portfolio designed to improve how therapies are developed, manufactured, and delivered to patients with difficult-to-treat diseases.
The company’s Deciparticle platform, developed through its relationship with Sapu Nano, addresses long-standing challenges with hydrophobic drugs, which often suffer from poor solubility and limited bioavailability. This technology is central to Oncotelic’s strategy to enhance drug delivery and therapeutic efficacy.
Additionally, the PDAOAI ecosystem now incorporates 28 million scientific abstracts, providing a vast knowledge base for AI-driven drug discovery and development. This system is being deployed in real-world pharmaceutical automation applications through TechForce Robotics, enabling faster and more efficient processes.
Oncotelic’s integration of nanomedicine, AI, and robotics has significant implications for the future of medicine. By leveraging these technologies, the company aims to accelerate the development of therapies for cancer and rare diseases, potentially bringing new treatments to patients more quickly. The combination of AI-driven insights and robotic automation could also reduce costs and improve scalability in drug manufacturing.
For more information on Oncotelic’s recent developments, visit their newsroom at ibn.fm/OTLC and read the full press release at ibn.fm/lU39h.
InvestorWire, a specialized communications platform, syndicated this press release. For more details, visit their website at https://www.InvestorWire.com.
